IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 372 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 1.32 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,396 | -39.3% | 50,264 | -44.8% | 0.00% | -50.0% |
Q1 2024 | $3,950 | +18.6% | 91,101 | +38.4% | 0.01% | 0.0% |
Q4 2023 | $3,331 | +13.5% | 65,831 | +1.8% | 0.01% | 0.0% |
Q3 2023 | $2,934 | +128.0% | 64,687 | +106.3% | 0.01% | +100.0% |
Q2 2023 | $1,287 | +87.9% | 31,361 | +63.6% | 0.00% | +50.0% |
Q1 2023 | $685 | +50.5% | 19,175 | +59.2% | 0.00% | +100.0% |
Q4 2022 | $455 | -99.3% | 12,042 | +749.8% | 0.00% | – |
Q3 2022 | $63,000 | -98.9% | 1,417 | -99.0% | 0.00% | -100.0% |
Q2 2021 | $5,879,000 | -23.1% | 147,383 | -13.3% | 0.01% | -33.3% |
Q1 2021 | $7,643,000 | +6.7% | 169,992 | +34.2% | 0.02% | 0.0% |
Q4 2020 | $7,160,000 | -40.1% | 126,643 | -49.7% | 0.02% | +10.5% |
Q3 2020 | $11,950,000 | -29.1% | 251,836 | -11.9% | 0.02% | -34.5% |
Q2 2020 | $16,854,000 | +336.0% | 285,858 | +249.6% | 0.03% | +45.0% |
Q1 2020 | $3,866,000 | -38.4% | 81,766 | -21.3% | 0.02% | -16.7% |
Q4 2019 | $6,280,000 | -0.4% | 103,961 | -1.2% | 0.02% | -20.0% |
Q3 2019 | $6,304,000 | -5.6% | 105,218 | +1.3% | 0.03% | -6.2% |
Q2 2019 | $6,676,000 | -32.8% | 103,882 | -15.1% | 0.03% | -34.7% |
Q1 2019 | $9,933,000 | +38.3% | 122,373 | -7.9% | 0.05% | +36.1% |
Q4 2018 | $7,183,000 | +1.3% | 132,876 | -3.3% | 0.04% | +2.9% |
Q3 2018 | $7,091,000 | +24.5% | 137,471 | +0.6% | 0.04% | +29.6% |
Q2 2018 | $5,696,000 | +12.2% | 136,696 | +18.7% | 0.03% | +8.0% |
Q1 2018 | $5,077,000 | -40.4% | 115,186 | -32.0% | 0.02% | -40.5% |
Q4 2017 | $8,518,000 | -34.8% | 169,347 | -34.3% | 0.04% | -37.3% |
Q3 2017 | $13,066,000 | +7.4% | 257,705 | +7.8% | 0.07% | 0.0% |
Q2 2017 | $12,166,000 | +34.0% | 239,160 | +5.9% | 0.07% | +67.5% |
Q1 2017 | $9,081,000 | -9.2% | 225,907 | +8.0% | 0.04% | -20.0% |
Q4 2016 | $10,005,000 | +44.2% | 209,178 | +10.5% | 0.05% | +56.2% |
Q3 2016 | $6,938,000 | +28.2% | 189,354 | -18.5% | 0.03% | +14.3% |
Q2 2016 | $5,412,000 | -37.3% | 232,391 | +9.1% | 0.03% | -51.7% |
Q1 2016 | $8,629,000 | -51.9% | 213,069 | -26.4% | 0.06% | -59.2% |
Q4 2015 | $17,931,000 | – | 289,544 | – | 0.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sicart Associates LLC | 367,360 | $14,768,000 | 10.67% |
BB BIOTECH AG | 7,461,295 | $299,944,000 | 9.81% |
TANAKA CAPITAL MANAGEMENT INC | 83,399 | $3,353,000 | 7.39% |
DOWLING & YAHNKE LLC | 675,843 | $27,169,000 | 2.89% |
Opus Point Partners Management, LLC | 78,900 | $3,172,000 | 2.35% |
Motley Fool Asset Management LLC | 259,000 | $10,412,000 | 2.25% |
ARK Investment Management | 127,563 | $5,128,000 | 1.48% |
Motley Fool Wealth Management, LLC | 325,965 | $13,104,000 | 1.26% |
PINNACLE ASSOCIATES LTD | 1,514,710 | $60,891,000 | 1.16% |
Bellevue Group AG | 205,253 | $8,251,000 | 1.10% |